Amanta Healthcare Limited has launched its Initial Public Offering (IPO) in September 2025. The company, known for its sterile liquid products such as large volume parenterals (LVPs) and small volume parenterals (SVPs), is entering the market with a book-built issue. In this article, we cover the Amanta Healthcare IPO GMP (Grey Market Premium), IPO price band, lot size, subscription dates, company financials, and complete review to help investors make an informed decision.
Amanta Healthcare IPO Details
- IPO Type: Book-Built
- IssueIssue Size: 10,000,000
- equity sharesFace Value: ₹10 per share
- Price Band: ₹120 – ₹126 per share
- Lot Size: Retail investors can apply in multiples of the lot (as per RHP guidelines).
- Issue Opens: 1st September 2025
- Issue Closes: 3rd September 2025
- Listing on: NSE and BSE.
Amanta Healthcare IPO GMP (Grey Market Premium)
The Amanta Healthcare IPO GMP has been a hot topic among retail investors. On the first day of subscription, the GMP stood at around +22%, which means shares were trading in the grey market at a premium of ₹26–28 over the upper band of ₹126.A positive GMP generally indicates strong listing expectations.However, GMP is unofficial and volatile, so investors should not rely solely on it while applying.
Anchor Investors and Pre-IPO Interest
Before the issue opened to the public, Amanta Healthcare raised ₹37.8 crore from anchor investors. Big names such as Bandhan Small Cap Fund, Sanshi Fund-1, Perpetuity H2W Rising Fund, Aarth Growth Fund, and Sunrise Investment Trust participated.
Anchor participation shows institutional confidence in the IPO.It also gives retail investors some assurance about the company’s credibility.
About Amanta Healthcare Limited
Amanta Healthcare is a pharmaceutical company engaged in the manufacturing of sterile liquid products.
Core Products: Large Volume Parenterals (LVPs), Small Volume Parenterals (SVPs), IV fluids, and hospital consumables.Customers: Hospitals, distributors, institutional buyers, and export markets.
Business Model: Direct sales, distribution network, and contract manufacturing.
Future Plans: Capacity expansion using IPO proceeds, improved production efficiency, and stronger domestic as well as export presence.
Manufacturing and Capacity
The company operates modern manufacturing facilities certified for pharma production.
1.Capacity Expansion: A major portion of IPO proceeds will be used to expand production.
2.Technology: Focus on sterile liquid packaging and parenteral solutions.
3.Market Reach: Strong presence in Indian hospitals and also exports to select international market
Objects of the Issue
According to the RHP (Red Herring Prospectus), the IPO proceeds will be utilized for:
1. Capacity expansion at existing manufacturing plants.
2. Working capital requirements to support growing business.
3. General corporate purposes including debt reduction and operational improvements.
Amanta Healthcare Financial Performance
Here are the key highlights of the restated financials as per the RHP (₹ in lakhs):
Revenue (Total Income)
FY2023: ~₹27,000 lakhs
FY2024: ₹28,160.68 lakhs
FY2025: ₹27,332.09 lakhs
Profit After Tax (PAT)
FY2023: Loss of ₹211.06 lakhs
FY2024: Profit of ₹363.32 lakhs
FY2025: Profit of ₹1,050.07 lakhs
Net Worth
FY2025: ₹9,638.83 lakhs
Earnings Per Share (EPS)
FY2024: ₹1.35
FY2025: ₹3.71
Observation
The company turned profitable in FY2024 after a loss in FY2023.PAT jumped significantly in FY2025, indicating strong recovery and growth.
Revenue growth has been stable but slightly fluctuating due to working capital pressure.
Valuation and IPO Price Justification
At the upper price band of ₹126, the stock is valued at a P/E ratio of ~40–45x (based on FY25 EPS).Considering the healthcare and pharma sector average, valuations are slightly on the higher side.
However, the company’s growth potential and expansion plans may justify the premium.
Strengths of Amanta Healthcare IPO
- Strong presence in sterile liquids segment (high demand in hospitals).
- Growing profitability (PAT increased 3x in FY25 compared to FY24).
- Participation from reputed anchor investors.
- Expanding manufacturing capacity with IPO funds.
- Opportunities in export markets.
Risks and Concerns
- Debt Levels: Historically high borrowings; interest burden can affect profits.
- Raw Material Volatility: Any rise in packaging and pharma ingredients cost may reduce margins.
- Regulatory Compliance: Pharma sector is highly regulated; any violation can impact operations.
- Competition: Faces stiff competition from established pharma giants and other contract manufacturers.
- Customer Concentration: Dependency on key distributors/customers can be risky.
Amanta Healthcare IPO Review – Should You Apply?
For Listing Gains: The strong GMP of +22% indicates chances of a positive listing. Short-term investors may consider applying.
For Long-Term Investment: Fundamentals are improving but debt and valuations are a concern. If the company successfully expands capacity and maintains profitability, long-term returns can be attractive.
Verdict: Suitable for investors looking for a mix of growth and moderate risk. Conservative investors should wait for post-listing performance.
Conclusion
The Amanta Healthcare IPO is attracting attention in September 2025 due to its strong grey market premium, anchor investor interest, and improving financials. While risks like debt burden and regulatory compliance exist, the company’s focus on sterile liquid products and hospital demand makes it an interesting bet in the healthcare sector.